Products from BPS Bioscience require a minimum order value above 400€
Applications: This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-BCMA-anti-CD3-Avi-His-Tag can be used for studying BCMA+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell l
Background: B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. Upregulations of BCMA also correlates with disease burden and pro prognosis in multiple myeloma. This bispecific antibody binds to BCMA on cancer cells and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to the cancer cells. The binding event potentiates unstimulated T cells and induces direct cytotoxicity against BCMA+ cancer cells.
Description: Anti-BCMA-Anti-CD3-Avi-His-Tag is a purified recombinant human bispecific antibody with T cell Engager. This bispecific antibody has been tested for specific activity in both ELISA binding assay to BCMA-biotin and functional reporter assay using NFAT-luc reporter Jurkat cell line (BPS Bioscience #60621) in the presence of BCMA-CHO cells (BPS Bioscience #79500-H).
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol
Purification: Ni-NTA affinity purification of the His-tag protein from HEK293 cells.
Storage Stability: Stable for at least 12 months at -80°C. Avoid freeze/thaw cycles.
Supplied As: Aqueous buffer solution.
Tags: C-terminal Avi-His-tag
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
English
Deutsch
